Present situation and advances on the nimotuzumab related radiosensitivity research
10.11904/j.issn.1002-3070.2015.03.012
- VernacularTitle:尼妥珠单抗的放疗增敏研究现状及进展
- Author:
Kai TENG
;
Yong ZHANG
;
Li LIU
- Publication Type:Journal Article
- Keywords:
Nimotuzumab;
Radiosensitivity;
Cancer
- From:Practical Oncology Journal
2015;(3):245-249
- CountryChina
- Language:Chinese
-
Abstract:
With data support from abundant research ,epithelial growth factor receptor ( EGFR) signaling pathway is associated with radiotherapy resistance .EGFR inhibition has become one of methods to increase radio-sensitivity.As the first EGFR monoclonal antibody developed by China and Cuba ,nimotuzumab demonstrates its distinct clinical characteristics and has been extensively explored in head and neck cancer , esophageal cancer , high grade glioma .This article mainly reviews the present situation and recent advances on the radiosensitivity re -search of nimotuzumab .
